



About Laguna Pharmaceuticals

Laguna Pharmaceuticals is a biopharmaceutical company advancing vanoxerine for the treatment of atrial fibrillation and atrial flutter. The company has raised \$35 million in venture funding to date from BioMed Ventures, Frazier Healthcare, Santé Ventures and Versant Ventures.

About Vanoxerine

Vanoxerine is a Phase 3 ready therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. It inhibits the hERG ion channel, which is implicated in the management of electrical signaling to the heart, as well as L-type calcium and sodium channels. In clinical studies conducted to date, vanoxerine has demonstrated positive safety and tolerability. An oral formulation of vanoxerine is being developed to potentially meet needs in both hospital and home settings.

Data from COR-ART: Phase 2b Study

In a Phase 2b clinical study, vanoxerine demonstrated statistically improvement, compared to placebo, in converting heart rhythms from irregular to normal. With the 400 mg dose, 84 percent of patients converted to normal sinus rhythm within 24 hours. This benefit neared the level achieved with direct current cardioversion – an aggressive procedure that sends an electric shock to the heart. Also at this dose, 76 percent of patients achieved normal sinus rhythm in the first eight hours. Vanoxerine demonstrated positive, dose-dependent efficacy at all doses evaluated. It was well-tolerated with no serious adverse events related to the study drug.

About Atrial Fibrillation

Atrial fibrillation is the leading form of irregular heartbeat, known as arrhythmia, which causes poor blood flow in patients. Patients often experience heart palpitations, shortness of breath and weakness that can make daily activities challenging. In addition, prolonged arrhythmia has been linked to the formations of blood clots that may form blockages. There are an estimated 2.3 million patients in the United States today, with rates rising steadily and expected to double by 2040. The condition is often treated through direct current cardioversion, an aggressive, in-hospital medical procedure that sends an electric shock to the heart. Even after successful treatment, patients can develop the arrhythmia again – requiring retreatment in a hospital setting. Pharmaceutical treatments are an attractive alternative, if effective, as they could allow for easier, lower-cost treatment and potentially at a patient's own home.

Executive Team

Bob Baltera, CEO

Howard Dittrich, M.D., CMO

Brian Farmer, CBO

Board of Directors

Bob Baltera

Jerel Davis, Ph.D., Versant Ventures

Kevin M. Lalande, Santé Ventures

James Topper, M.D., Ph.D., Frazier Healthcare

Investors

BioMed Ventures

Frazier Healthcare

Santé Ventures

Versant Ventures